Conditions: Anxiety Disorders
Keywords: Generalised Anxiety Disorder GAD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 450
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.

PLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Detailed description:

Arms:
arm 1: Tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily. arm 2: Matching placebo tablets orally administered once daily.

Interventions: intervention 1: Quetiapine XR intervention 2: Placebo
Intervention descriptions: intervention 1: Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period. intervention 2: Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.

Protocol document: